GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolva Holding SA en liquidation (OTCPK:ELVYY) » Definitions » Research & Development

Evolva Holding en liquidation (Evolva Holding en liquidation) Research & Development : $36.58 Mil (TTM As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Evolva Holding en liquidation Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Evolva Holding en liquidation's Research & Development for the six months ended in Jun. 2023 was $32.11 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $36.58 Mil.


Evolva Holding en liquidation Research & Development Historical Data

The historical data trend for Evolva Holding en liquidation's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolva Holding en liquidation Research & Development Chart

Evolva Holding en liquidation Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.74 13.98 15.26 24.37 25.33

Evolva Holding en liquidation Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.84 6.78 20.03 4.48 32.11

Evolva Holding en liquidation Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $36.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolva Holding en liquidation  (OTCPK:ELVYY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Evolva Holding en liquidation Research & Development Related Terms

Thank you for viewing the detailed overview of Evolva Holding en liquidation's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolva Holding en liquidation (Evolva Holding en liquidation) Business Description

Traded in Other Exchanges
Address
Duggingerstrasse 23, Reinach, CHE, CH-4153
Evolva Holding SA en liquidation formerly Evolva Holding SA is a biotechnology company. The company is engaged in discovering, developing, and commercializing ingredients and biomanufacturing processes for nutrition, healthcare, and wellness products. Geographically, the company operates in Switzerland and the United States where Switzerland derives a majority of its revenue.

Evolva Holding en liquidation (Evolva Holding en liquidation) Headlines

From GuruFocus

Half Year 2023 Evolva Holding SA Earnings Call Transcript

By GuruFocus Research 02-13-2024